CHOP + ESHAP

CHOP + ESHAP is a combination chemotherapy regimen used primarily for the treatment of aggressive lymphomas such as peripheral T-cell lymphoma (PTCL) and relapsed or refractory non-Hodgkin's lymphoma. The regimen alternates cycles of two multi-drug protocols: - **CHOP** consists of cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone. - **ESHAP** includes etoposide, methylprednisolone, high-dose cytarabine (Ara-C), and cisplatin. The mechanism of action involves multiple pathways: - Cyclophosphamide is an alkylating agent that crosslinks DNA. - Doxorubicin intercalates DNA and inhibits topoisomerase II. - Vincristine disrupts microtubule formation. - Prednisone and methylprednisolone are corticosteroids with lympholytic effects. - Etoposide inhibits topoisomerase II. - Cytarabine is a nucleoside analog that inhibits DNA synthesis. - Cisplatin forms DNA crosslinks leading to apoptosis. This intensive alternating regimen aims to maximize tumor cell kill by using drugs with different mechanisms. It is often followed by autologous stem cell transplantation in eligible patients[2][1][5].

Other names

cyclophosphamide + doxorubicin + vincristine + prednisone + etoposide + methylprednisolone + cytarabine + cisplatin